167 related articles for article (PubMed ID: 16462496)
1. Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT.
Einhorn LH; Brames MJ; Heinrich MC; Corless CL; Madani A
Am J Clin Oncol; 2006 Feb; 29(1):12-3. PubMed ID: 16462496
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
Hotte SJ; Winquist EW; Lamont E; MacKenzie M; Vokes E; Chen EX; Brown S; Pond GR; Murgo A; Siu LL
J Clin Oncol; 2005 Jan; 23(3):585-90. PubMed ID: 15659505
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
Krug LM; Crapanzano JP; Azzoli CG; Miller VA; Rizvi N; Gomez J; Kris MG; Pizzo B; Tyson L; Dunne M; Heelan RT
Cancer; 2005 May; 103(10):2128-31. PubMed ID: 15812822
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of imatinib in patients with small cell lung cancer.
Johnson BE; Fischer T; Fischer B; Dunlop D; Rischin D; Silberman S; Kowalski MO; Sayles D; Dimitrijevic S; Fletcher C; Hornick J; Salgia R; Le Chevalier T
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5880-7. PubMed ID: 14676110
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.
Modi S; Seidman AD; Dickler M; Moasser M; D'Andrea G; Moynahan ME; Menell J; Panageas KS; Tan LK; Norton L; Hudis CA
Breast Cancer Res Treat; 2005 Mar; 90(2):157-63. PubMed ID: 15803362
[TBL] [Abstract][Full Text] [Related]
6. Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors.
Chao J; Budd GT; Chu P; Frankel P; Garcia D; Junqueira M; Loera S; Somlo G; Sato J; Chow WA
Anticancer Res; 2010 Feb; 30(2):547-52. PubMed ID: 20332468
[TBL] [Abstract][Full Text] [Related]
7. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R.
Gross DJ; Munter G; Bitan M; Siegal T; Gabizon A; Weitzen R; Merimsky O; Ackerstein A; Salmon A; Sella A; Slavin S;
Endocr Relat Cancer; 2006 Jun; 13(2):535-40. PubMed ID: 16728580
[TBL] [Abstract][Full Text] [Related]
8. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
[TBL] [Abstract][Full Text] [Related]
9. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
Heinrich MC; Joensuu H; Demetri GD; Corless CL; Apperley J; Fletcher JA; Soulieres D; Dirnhofer S; Harlow A; Town A; McKinley A; Supple SG; Seymour J; Di Scala L; van Oosterom A; Herrmann R; Nikolova Z; McArthur AG;
Clin Cancer Res; 2008 May; 14(9):2717-25. PubMed ID: 18451237
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
11. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
Wyman K; Atkins MB; Prieto V; Eton O; McDermott DF; Hubbard F; Byrnes C; Sanders K; Sosman JA
Cancer; 2006 May; 106(9):2005-11. PubMed ID: 16565971
[TBL] [Abstract][Full Text] [Related]
12. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
[TBL] [Abstract][Full Text] [Related]
13. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
Chirieac LR; Trent JC; Steinert DM; Choi H; Yang Y; Zhang J; Patel SR; Benjamin RS; Raymond AK
Cancer; 2006 Nov; 107(9):2237-44. PubMed ID: 16998931
[TBL] [Abstract][Full Text] [Related]
14. Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate.
Swick BL; Ravdel L; Fitzpatrick JE; Robinson WA
J Cutan Pathol; 2007 Apr; 34(4):324-9. PubMed ID: 17381803
[TBL] [Abstract][Full Text] [Related]
15. A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours.
Baruchel S; Sharp JR; Bartels U; Hukin J; Odame I; Portwine C; Strother D; Fryer C; Halton J; Egorin MJ; Reis RM; Martinho O; Stempak D; Hawkins C; Gammon J; Bouffet E
Eur J Cancer; 2009 Sep; 45(13):2352-9. PubMed ID: 19505817
[TBL] [Abstract][Full Text] [Related]
16. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
Blanke CD; Rankin C; Demetri GD; Ryan CW; von Mehren M; Benjamin RS; Raymond AK; Bramwell VH; Baker LH; Maki RG; Tanaka M; Hecht JR; Heinrich MC; Fletcher CD; Crowley JJ; Borden EC
J Clin Oncol; 2008 Feb; 26(4):626-32. PubMed ID: 18235122
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands.
Pfeffer MR; Talmi Y; Catane R; Symon Z; Yosepovitch A; Levitt M
Oral Oncol; 2007 Jan; 43(1):33-6. PubMed ID: 16757202
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.
Bond M; Bernstein ML; Pappo A; Schultz KR; Krailo M; Blaney SM; Adamson PC
Pediatr Blood Cancer; 2008 Feb; 50(2):254-8. PubMed ID: 17262795
[TBL] [Abstract][Full Text] [Related]
19. Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies.
Beer TM; Tangen CM; Nichols CR; Margolin KA; Dreicer R; Stephenson WT; Quinn DI; Raghavan D; Crawford ED
Cancer; 2006 Jun; 106(12):2624-9. PubMed ID: 16688776
[TBL] [Abstract][Full Text] [Related]
20. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
